Status:
WITHDRAWN
The Effect of Cannabis in Pancreatic Cancer
Lead Sponsor:
Jens Rikardt Andersen
Conditions:
Neoplasms Pancreatic
Cachexia; Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test ...
Detailed Description
Randomization of consecutive patients who wanted to participate to a daily dose of CBD or not as a supplement to the standard treatment.
Eligibility Criteria
Inclusion
- Adult, palliative pancreatic cancer diagnosis, weight loss \> 5%, understand and read Danish.
Exclusion
- Regular use of cannabis, psychiatric disorders, alcohol abuse, life expectancy \< 6 months
Key Trial Info
Start Date :
October 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 6 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03245658
Start Date
October 6 2017
End Date
October 6 2018
Last Update
December 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of clinical oncology, Næstved-Roskilde Hospital
Næstved, Denmark, 4700